Page last updated: 2024-12-11
nidulin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nidulin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6450195 |
CHEMBL ID | 3358704 |
SCHEMBL ID | 5805959 |
SCHEMBL ID | 16435037 |
MeSH ID | M0052615 |
Synonyms (22)
Synonym |
---|
o-methylustin |
1329-04-0 |
11h-dibenzo(b,e)(1,4)dioxepin-11-one, 2,4,6(or 2,4,7)-trichloro-3-hydroxy-8-methoxy-1,9-dimethyl-7(or 6)-(1-methyl-1-propenyl)- |
nidulin |
1-[(e)-but-2-en-2-yl]-2,8,10-trichloro-9-hydroxy-3-methoxy-4,7-dimethylbenzo[b][1,4]benzodioxepin-6-one |
SCHEMBL5805959 |
4,2-cresotic acid, 3,5-dichloro-6-(5-chloro-2-hydroxy-4-methoxy-6-(1-methylpropenyl)-m-tolyloxy)-, epsilon-lactone |
unii-5zeg4ds0u1 |
4,2-cresotic acid, 3,5-dichloro-6-(5-chloro-2-hydroxy-4-methoxy-6-(1-methylpropenyl)-m-tolyloxy)-, .epsilon.-lactone |
11h-dibenzo(b,e)(1,4)dioxepin-11-one, 2,4,7-trichloro-3-hydroxy-8-methoxy-1,9-dimethyl-6-(1-methyl-1-propenyl)-, (e)- |
nidulin [mi] |
ustin methyl ether |
5ZEG4DS0U1 , |
methylustin |
1402-15-9 |
J-000245 |
SCHEMBL16435037 |
CHEMBL3358704 |
2,8,10-trichloro-9-hydroxy-3-methoxy-4,7-dimethyl-1-[(e)-1-methylprop-1-enyl]benzo[b][1,4]benzodioxepin-6-one |
DTXSID501017592 |
Q27263102 |
AKOS040755905 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (13)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1753911 | Cytotoxicity against African green monkey Vero cells by colorimetric assay | |||
AID1753906 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition incubated for 18 hrs by CLSI protocol based agar microdilution method | |||
AID1753907 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition incubated for 18 hrs by CLSI protocol based agar microdilution method | |||
AID1753909 | Antifungal activity against Cryptococcus neoformans ATCC 90113 assessed as fungal growth inhibition incubated for 24 to 48 hrs by CLSI protocol based agar microdilution method | |||
AID1753915 | Antifungal activity against Cryptococcus neoformans ATCC 90113 assessed as fungal growth inhibition by CLSI protocol based assay | |||
AID1753908 | Antifungal activity against Candida albicans NCPF 90028 assessed as fungal growth inhibition incubated for 24 to 48 hrs by CLSI protocol based agar microdilution method | |||
AID1753917 | Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay | |||
AID1753912 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition by CLSI protocol based assay | |||
AID1753913 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition by CLSI protocol based assay | |||
AID1753921 | Antifungal activity against Microsporum gypseum assessed as fungal growth inhibition at 50 ug/ml by CLSI protocol based assay | |||
AID1753910 | Antifungal activity against Microsporum gypseum assessed as fungal growth inhibition incubated for 4 days by CLSI protocol based agar microdilution method | |||
AID1174113 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
AID1753920 | Antifungal activity against Candida albicans NCPF 90028 assessed as fungal growth inhibition at 50 ug/ml by CLSI protocol based assay | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.01) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |